Details for Patent: 8,871,779

Which drugs does patent 8,871,779 protect, and when does it expire?

Patent 8,871,779 protects OPANA ER and is included in two NDAs.

This patent has eleven patent family members in nine countries.

Summary for Patent: 8,871,779

Title:	Process for preparing morphinan-6-one products with low levels of .alpha.,.beta.-unsaturated ketone compounds
Abstract:	The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of .alpha.,.beta.-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. (A) ##STR00001##
Inventor(s):	Buehler; Henry J. (St. Louis, MO), Dummitt; William E. (St. Louis, MO), Mannino; Anthony (Maryland Heights, MO), Aubuchon; Dennis C. (Arnold, MO), Gu; Hong (Oak Park, CA)
Assignee:	Mallinckrodt LLC (Hazelwood, MO)
Application Number:	11/915,606
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,871,779
Patent Claim Types: see list of patent claims	Compound; Formulation;

Detailed Analysis of the Scope and Claims of United States Patent 8,871,779

Introduction

The United States Patent 8,871,779, hereafter referred to as the '779 patent, is a significant patent in the pharmaceutical industry, particularly in the context of drug purification. This analysis will delve into the scope, claims, and the patent landscape surrounding this patent.

Patent Overview

Patent Title and Assignee

The '779 patent, titled "Compositions of oxymorphone having a low level of 14-hydroxymorphinone," is assigned to Endo Pharmaceuticals Inc.

Background

Oxymorphone is an opioid used for treating pain, and the '779 patent focuses on compositions of this drug with a very low level of a specific contaminant, 14-hydroxymorphinone (ABUK)[4].

Claims of the Patent

Claim 1

The primary claim of the '779 patent is directed to a hydrochloride salt of oxymorphone comprising less than 0.001% of 14-hydroxymorphinone. This claim is crucial as it specifies the composition of the drug with a particular purity level, which is a key innovation[4].

Claim Scope

The claims are not limited to the method of purification but also cover the composition itself. This is significant because it allows the patentee to secure exclusive rights to the purified drug composition, rather than just the method of purification[4].

Obviousness and Prior Art

FDA Mandate

A critical aspect of the '779 patent is the FDA mandate that required opioid manufacturers to reduce ABUK impurities in oxymorphone to below 0.001%. This mandate was a key factor in the purification process, but the court held that it did not render the composition obvious. The majority opinion stated that the FDA mandate provided a motivation to solve the problem but did not make the composition itself obvious[4].

Prior Art References

The district court considered three prior art references disclosing purification methods but found that these references did not make the claimed composition obvious. The court also did not consider the FDA communication as prior art, which was a point of contention in the appeal[4].

Patent Landscape Analysis

Patent Saturation

The '779 patent operates in a highly saturated patent area within the pharmaceutical industry. A patent landscape analysis would reveal numerous patents related to drug purification and composition. This saturation indicates a competitive and innovative field where companies are continually seeking to improve drug purity and efficacy[3].

Strategic Insights

A comprehensive patent landscape analysis would help Endo Pharmaceuticals and other stakeholders understand the broader technology area. This analysis can highlight areas of high patent saturation, indicating mature technologies, and areas with less saturation, suggesting opportunities for new inventions. For example, if a company sees high patent saturation in drug purification methods, it might consider pivoting to newer inventive spaces such as novel drug delivery systems or other therapeutic areas[3].

Legal and Regulatory Environment

Obviousness Standard

The '779 patent has been subject to scrutiny under the obviousness standard. The court's decision to uphold the patent's validity despite the FDA mandate underscores the complexity of determining obviousness. The majority opinion emphasized that the patent system is designed to protect innovations that result from significant efforts, even if those efforts are in response to regulatory requirements[4].

Post-Mayo/Alice Analysis

The analysis of the '779 patent also reflects the post-Mayo/Alice landscape in patent law, where the focus is on what the invention is "directed to" rather than just the claim form. This approach encourages a deeper examination of the invention's substance and its contribution to the field[4].

Industry Impact

Competitive Landscape

The '779 patent is part of a larger competitive landscape in the pharmaceutical industry. Companies like Endo Pharmaceuticals must navigate this landscape carefully, ensuring that their innovations are protected while also complying with regulatory requirements. The patent's validity affects not only Endo but also other manufacturers and generic drug producers[4].

Public Policy

The dissenting opinion in the case highlighted a broader public policy debate about the scope of patent protection in the pharmaceutical industry. There is a growing movement to reign in what some see as overly broad patent protections, particularly in cases where the innovation seems to be more about compliance with regulatory mandates rather than groundbreaking research[4].

Key Takeaways

• Composition Claims: The '779 patent covers not just the method of purification but also the composition of oxymorphone with a specific purity level.
• Obviousness: The patent was upheld despite an FDA mandate, emphasizing that regulatory compliance does not necessarily make an invention obvious.
• Patent Landscape: The patent operates in a highly saturated area, indicating a competitive and innovative field.
• Legal Environment: The patent's validity reflects the post-Mayo/Alice analysis, focusing on the substance of the invention.
• Industry Impact: The patent affects the competitive landscape and public policy debates in the pharmaceutical industry.

FAQs

Q: What is the main claim of the '779 patent?

A: The main claim is directed to a hydrochloride salt of oxymorphone comprising less than 0.001% of 14-hydroxymorphinone.

Q: Why was the FDA mandate not considered prior art?

A: The court did not consider the FDA mandate as prior art because it provided a motivation to solve the problem but did not make the composition itself obvious.

Q: How does the '779 patent fit into the broader patent landscape?

A: The patent operates in a highly saturated area of drug purification and composition, indicating a competitive and innovative field.

Q: What is the significance of the post-Mayo/Alice analysis in this case?

A: The analysis focuses on what the invention is "directed to," encouraging a deeper examination of the invention's substance and its contribution to the field.

Q: What public policy debates are relevant to the '779 patent?

A: The patent is part of broader debates about the scope of patent protection in the pharmaceutical industry, particularly regarding innovations that seem to be more about regulatory compliance than groundbreaking research.

Sources

1. Endo Pharm. Inc. v. Actavis LLC, 922 F.3d 1365 - Casetext
2. IP Alert: Do Words Have a Magic Effect in Patent Law? - Banner Witcoff
3. Patent Landscape Analysis - Uncovering Strategic Insights - AcclaimIP
4. Endo Pharm. Inc. v. Actavis LLC - Casetext

Drugs Protected by US Patent 8,871,779

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-001	Jun 22, 2006		DISCN	Yes	No				Y
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-005	Feb 29, 2008		DISCN	Yes	No				Y
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-002	Jun 22, 2006		DISCN	Yes	No				Y
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-006	Feb 29, 2008		DISCN	Yes	No				Y
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-003	Jun 22, 2006		DISCN	Yes	No				Y
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-007	Feb 29, 2008		DISCN	Yes	No				Y
Endo Operations	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-004	Jun 22, 2006		DISCN	Yes	No				Y

Foreign Priority and PCT Information for Patent: 8,871,779

PCT Information
PCT Filed	March 02, 2007	PCT Application Number:	PCT/US2007/005256
PCT Publication Date:	September 13, 2007	PCT Publication Number:	WO2007/103105

International Family Members for US Patent 8,871,779

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E448231
Australia	2007224221
Canada	2644095
China	101395159
Germany	602007003197
European Patent Office	1994034
Japan	2009528366